Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...

Related Keywords

Texas ,United States ,Jim Kastenmayer ,Aeglea Biotherapeutics ,Piper Sandler ,Exchange Commission ,Jp Morgan ,European Medicines Agency ,Drug Administration ,Prnewswire Aeglea Biotherapeutics Inc ,Aeglea Biotherapeutics Inc ,Nasdaq ,Interim Clinical Data ,Pegtarviliase Expected ,Fourth Quarter ,Currently Dosing Cohort ,Classical Homocystinuria ,Marketing Authorization Application ,Key Opinion Leader ,Authorization Application ,Middle East ,Biologics License Application ,Inborn Errors ,Annual Healthcare Conference ,Annual Evercore ,Sci Advisors Corporate Access Event ,Annual Healthcare Meeting ,Drug Designation ,Pediatric Disease ,Rare Pediatric Disease ,Breakthrough Therapy ,Fast Track ,Orphan Drug ,Orphan Drug Designation ,European Medicines ,Forward Looking ,Securities Litigation Reform Act ,Quarterly Report ,Consolidated Statements ,Nc ,